551
Participants
Start Date
June 30, 2003
Primary Completion Date
July 31, 2008
Study Completion Date
July 31, 2008
Exenatide (AC2993)
subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
Insulin glargine
subcutaneous injection, once daily; forced titration to target blood glucose level
Sykehuset Asker of Baerum HF, Rud
Spesiallegetjenesten AS, Jessheim
Royal North Shore Hospital, St Leonards
A.Z. Jan Palfijn, Merksem
Australian Clinical Research Centre, Miranda
Clinical Trial and Research Unit, Wollongong
UZ Antwerpen, Endegem
UZ Gasthuisberg, Leuven
Royal Melbourne Hospital, Parkville
Eastern Health (Box Hill Hospital), Box Hill
CHU Sart Tilman, Liège
Forskningsstiftelsen Hjertelaget, Stravanger
Royal Brisbane Hospital, Brisbane
Royal Adelaid Hospital, Adelaid
Markeveien Spesialistpraksis, Bergen
SA Endocrine Clinical Research, Keswick
Repatriation General Hospital, Daw Park
UZ Gent, Ghent
Sint Niklaasstraat, Sint-Gillis-Waas
DOCS, Beth Israel Medical Center, Yonkers
Great Lakes Medical Research, Westfield
Jon Shapiro, MD, Philadelphia
Krankenhaus Bethanien, Hamburg
Frederick Primary Care Associates, Frederick
Piedmont Medical Research Associates, Winston-Salem
Hospital Doce de Octubre, Madrid
Jacksonville Center for Clinical Research, Jacksonville
Baptist Diabetes Associates, Miami
Metabolic Research Institute, Inc., West Palm Beach
Internal Medicine Associates Department of Research, Fort Myers
Endocrinology Consultants of East Tennessee, Knoxville
Hospital Virgen de Valme, Seville
Diabetologische Schwerpunktpraxis, Dortmund
Diabetologische Scherpunktpraxis, Bosenheim
Diabetologische Schwerpunktpraxis, Neuwied
Springfield Diabetes & Endocrine Center, Springfield
Radiant Research, Inc., St Louis
Diabetologische Schwerpunktpraxis, Aschaffenburg
Universitatskliniken des Saarlandes, Homburg/Saar
Israel Hartman, MD, Arlington
Diabetes & Glandular Research Associates, P.A., San Antonio
Jack Wahlen, MD, Ogden
Lovelace Scientific Resources, Albuquerque
Lovelace Scientific Resources, Inc., Las Vegas
Oulu Deakoness Institution, Oulu
Radiant Research-San Diego, San Diego
Dorothy L. and James E. Frank Diabetes Research Institute, San Mateo
Rainier Clinical Research Center, Inc., Renton
Diabetes, Endocrine & Nutrition, Hampton
Freemantle Hospital, Freemantle
Eiran Sairaala c/o9 Clires, Helsinki
Torikeskuksen Laakariasema, Yliopistonkatu, Jyväskylä
IKFE GmbH, Mainz
Profil Institut fur Stoffwechselforschung GmbH, Neuss
Medisch Centrum, Westeinde
"NZOZ Diab-Endo-Met", Krakow
Hospital Nossa Senhora das Gracas, Curitiba
Centro Integrado de Diabetes e Hipertensao, Fortaleza
Centro de Pesquisas em Diabetes e Doencas Endocrino Metabolicas/HUWC/UFC, Fortaleza
Santa Casa de Misericordia de Porto Alegre, Porto Alegre
Diabetes Centrum Bilthoven, Bilthoven
Atrium Medisch Centrum Brunssum, Brunssum
Sint Antonius Ziekenhuis Nieuwegein, Nieuwegein
Refaja ziekenhuis, Stadskanaal
Betanien Spesialistsenter, Oslo
Bydgoskie Centrum Diabetologii i Endokrynologii, Bydgoszcz
Oddzial Chorob Wewnetrznych, Częstochowa
Poradnia Diabetologiczna, Lodz
Poradnia Diabetologiczna, Lublin
Oddzial Chorob Wewnetrznych, Mielec
Oddzial Chorob Wewnetrznych i Diabetologii, Warsaw
Wojewodzka Poradnia dla Chorych na Cukrzyce, Warsaw
Hospital Garcia de Orta-Servico de Endocrinologia, Almada
Centro Hospitalar de Coimbra, Coimbra
Associacao Protectora dos Diabeticos de Portugal, Lisbon
Hospital Geral de Santo Antonio, Porto
Universidad Central del Caribe, Bayamón
Hospital Alejandro Otero Lopez, Manatí
Dr. Luis Ruiz, Ponce
RCMI-Clinical Research Center, Rio Piedras
San Juan Health Center, San Juan
Centro de Endocrinologia del Este, Yabucoa
Hospital Vega Baja, Alicante
Hospital Gral de Mostoles, Madrid
Hospital la Ribera, Alzira, Valencia
Lundberglaboratoriet for diabetesforskning, Gothenburg
Medicinska kliniken, Helsingborg
Kliniska Forskningsenheren, Lund
Diabetesmottagningen, Intermedicinska kliniken, Stockholm
CME, M71, Stockholm
Enheten for metabol kontroll, Stockholm
Lead Sponsor
Eli Lilly and Company
INDUSTRY
AstraZeneca
INDUSTRY